Global adoption Nova Eye Medical provides iTrack MIGS and Molteno3 glaucoma devices used in over 100 countries, indicating a broad international sales opportunity with ophthalmology clinics and hospitals seeking minimally invasive glaucoma solutions.

Expansion momentum Recent financing rounds and expansion news, including a $6.6M financing for global growth and multiple congress appearances, suggest resources and market interest are aligned with scaling sales efforts in key regions.

US market focus Notable record US sales for iTrack Advance and ongoing product launches position Nova Eye to capitalize on a sizeable, reimbursement-driven market with established ophthalmic distributors and high surgical volume.

Clinical data leadership Publication of six-year data for iTrack canaloplasty microcatheter and continuous product innovations support value-based selling focused on improved patient outcomes, reduced medication dependence, and long-term cost savings for providers.

Strategic partnerships Participation in major ophthalmology congresses (DOG, ESCRS) and emphasis on canaloplasty technologies present opportunities to partner with clinics, training centers, and key opinion leaders to drive adoption and education.